Yancopoulos, Regeneron’s chief scientific officer ... technologies to deliver the first FDA-approved recombinant monoclonal antibody treatment for any viral disease, and they picked one of ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

A study finds that IN-006, a reformulated monoclonal antibody, is safe, well-tolerated, and delivers high antibody levels in the airway—offering a faster and more effective way to fight COVID-19.

Follow the latest COVID-19 Vaccine news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to COVID-19 Vaccine notifications.

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

now attracting attention as a potential therapy for COVID-19. The Regeneron alliance also yielded Sanofi’s under-performing cholesterol drug Praluent (alirocumab), which has failed to make much ...